Small cell lung cancers metastasize early in their course, so surgery is not usually an option (Spira and Ettinger, 2004). anchorite nodules with no metastases can be removed, followed by chemotherapy, usually of etoposide and cisplatin with vincristine, doxorubicin, and cyclophosphamide. confederacy of chemotherapy with radiation syndrome gives a moderate increase in benefits, and gives fall apart five year choice rates when used in concert rather than sequentially. Chemotherapy with cisplatin and etoposide is the treatment of choice for extensive disease.
A say of cisplatin-based adjuvant chemotherapy for patients with completely resected non-small-cell lung cancer involving 1867 patients was carried out based on a previous meta-analysis in the International Adjuvant Lung cancer Trial to evaluate the effect of cisplatin-based adjuvant therapy on survival in these patients (Cisplatin-based, 2004). The study was designed to show an absolute progression of survival at five years of from 50 percentage to 55 percent. Of the chemotherapy options chosen, 49.3 percent of patients selected a treatment of 100mg of cisplatin per square heartbeat of body-surface area for three or four cycles with etoposide.
Eight hundred-fifty-one patients real chemotherapy, and seven die
Although the study preceding(prenominal) gave virtually promising results for the use of cisplatin chemotherapy as adjuvant therapy adjacent surgery for non-small-cell lung cancer, it also raises many questions (Blum, 2004). The choice of chemotherapeutic federal agent used along with cisplatin does not seem to be important, only if the dose of cisplatin does, since many of the patients suffered from toxic side effects and several(prenominal) even died as a result.
The use of concurrent radiotherapy was not tested in this trial, though it was noted that some of the control mathematical group did have radiation therapy, and this could have been prudent for some of the deaths and other problems encountered.
Blum, R. H. 2004. Adjuvant chemotherapy for lung cancer - A newly standard of care. NEJM 350(4): 404-405.
2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: A randomized trial. JAMA 290(16): 2149.
d from toxic side effects of the therapy (Cisplatin-based, 2004). Nine-hundred-thirty-five patients served as the control group. The fatal toxic effects of cisplatin were 2.4 percent. Over the five years, 973 patients died, 469 in the chemotherapy group and 504 in the control group. The disease-free survival rate was significantly higher(prenominal) in the chemotherapy group than in the control group. This was the first trial to show that cisplatin chemotherapy improves survival in lung cancer patients. The absolute benefit in overall survival f
Ordercustompaper.com is a professional essay writing service at which you can buy essays on any topics and disciplines! All custom essays are written by professional writers!
No comments:
Post a Comment